KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Other financing activities (2016 - 2020)

Historic Other financing activities for Evolent Health (EVH) over the last 5 years, with Q2 2020 value amounting to -$33.7 million.

  • Evolent Health's Other financing activities fell 13115.22% to -$33.7 million in Q2 2020 from the same period last year, while for Sep 2020 it was -$104.9 million, marking a year-over-year decrease of 19191.18%. This contributed to the annual value of -$104.3 million for FY2019, which is 20843.97% down from last year.
  • Evolent Health's Other financing activities amounted to -$33.7 million in Q2 2020, which was down 13115.22% from $33.7 million recorded in Q1 2020.
  • Evolent Health's 5-year Other financing activities high stood at $113.5 million for Q4 2018, and its period low was -$107.5 million during Q1 2019.
  • Moreover, its 5-year median value for Other financing activities was $149500.0 (2017), whereas its average is -$291500.0.
  • Its Other financing activities has fluctuated over the past 5 years, first skyrocketed by 124050.0% in 2017, then tumbled by 346200.0% in 2018.
  • Quarter analysis of 5 years shows Evolent Health's Other financing activities stood at $1.6 million in 2016, then skyrocketed by 1240.5% to $21.4 million in 2017, then soared by 429.17% to $113.5 million in 2018, then plummeted by 192.4% to -$104.9 million in 2019, then skyrocketed by 67.89% to -$33.7 million in 2020.
  • Its Other financing activities was -$33.7 million in Q2 2020, compared to $33.7 million in Q1 2020 and -$104.9 million in Q4 2019.